A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Seasonal Allergic Rhinitis (SAR)

In brief

This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.

Key facts

Study ID

NCT07219849

Run by

Alixer Nexgen Therapeutics Limited

People needed

164

Starts

2025-10-17

Expected to finish

2026-04-01

Last updated by the study team

2025-10-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of Allergic Rhinitis (AR), as determined by the presence of seasonal rhinitis symptoms for several months per year, for more than 1 year and are not attributed to infections or nasal abnormalities
• Positive skin prick test (SPT) response to ragweed pollen (allergen induced wheal diameter at least 3 mm larger than the negative control) in the previous 12 months
• Healthy as determined by a responsible and experienced Investigator, based on a medical evaluation including medical history, physical examination, vital signs, ECG, and lab tests.

You may not qualify if…

• Nasal abnormalities likely to affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, sinusitis and other nasal malformations.
• History of frequent nosebleeds.
• Participants with rhinitis medicamentosa.
• Current or chronic history of hepatic disease.
• A QTcF (Fridericia-corrected QT interval) >450 ms in males or >470 ms in females.

Where it is running

• Cliantha Research — Mississauga, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.